-
公开(公告)号：US20100111965A1
公开(公告)日：2010-05-06
申请号：US12445109
申请日：2007-10-11
Applicant: James Johnston , Shane Olwill , Jill Brown , Nuala Morgan , Thomas Jaquin , Christopher Scott
Inventor： James Johnston , Shane Olwill , Jill Brown , Nuala Morgan , Thomas Jaquin , Christopher Scott
IPC: A61K39/395 , A61K31/7088 , C07K16/00 , A61P35/00 , C12Q1/68
CPC classification number: C12N15/1136 , A61K39/39558 , C07K16/22 , C07K2317/56 , C07K2317/73 , C12N2310/14 , C12N2320/31 , A61K2300/00
Abstract: The invention provides a method of treating neoplastic disease in a subject, said method comprising the simultaneous, sequential or separate, administration to said subject of an effective amount of (i) an inhibitor of a first EGF, e.g. HB-EGF and (ii) an inhibitor of a second EGF, e.g. AREG. Also described are novel synergistic combinations of EGF inhibitors with topoisomerase inhibitors which attenuate tumour cell growth. Further described are novel anti AREG antibodies.
Abstract translation: 本发明提供一种治疗受试者的肿瘤疾病的方法，所述方法包括向所述受试者施用有效量的（i）第一EGF的抑制剂，例如， HB-EGF和（ii）第二EGF的抑制剂，例如。 AREG。 还描述了EGF抑制剂与拓扑异构酶抑制剂的新的协同组合，其减弱肿瘤细胞生长。 进一步描述的是新的抗AREG抗体。
-
公开(公告)号：US09321838B2
公开(公告)日：2016-04-26
申请号：US12296704
申请日：2007-04-10
Applicant: Shane Olwill , Christopher Scott , Julie Gormley , Jaquin Thomas , Roberta Burden , Darragh McMeel , James Johnston
Inventor： Shane Olwill , Christopher Scott , Julie Gormley , Jaquin Thomas , Roberta Burden , Darragh McMeel , James Johnston
IPC: C07K16/00 , C07K16/28 , A61K31/00 , A61K39/395 , C07K16/40 , G01N33/574 , A61K39/00
CPC classification number: C07K16/28 , A61K31/00 , A61K39/3955 , A61K39/39558 , A61K2039/505 , C07K16/40 , C07K2317/76 , G01N33/57492 , A61K2300/00
Abstract: The invention relates to a method of inhibiting chemotherapy induced upregulation of Cathepsin S on the surface of tumor cells, the method comprising the administration of a Cathepsin S inhibitor to said cells. Also provided is a therapy comprising an anti Cathepsin S antibody, in particular an anti-Cathepsin S antibody which does not inhibit the proteolytic effect of Cathepsin S but nevertheless inhibits angiogenesis and a combination treatment comprising a Cathepsin S inhibitor and a therapeutic agent.
Abstract translation: 本发明涉及一种抑制化学疗法诱导肿瘤细胞表面组织蛋白酶S上调的方法，该方法包括向所述细胞施用组织蛋白酶S抑制剂。 还提供了包含抗组织蛋白酶S抗体，特别是不抑制组织蛋白酶S的蛋白水解作用但仍然抑制血管生成并且包含组织蛋白酶S抑制剂和治疗剂的组合治疗的抗组织蛋白酶S抗体的治疗剂。
-
公开(公告)号：US08846868B2
公开(公告)日：2014-09-30
申请号：US12988135
申请日：2009-04-17
Applicant: Jill Caswell , Shane Olwill , James Johnston , Richard Buick , Thomas Jaquin , Declan Doherty , Christopher Scott
Inventor： Jill Caswell , Shane Olwill , James Johnston , Richard Buick , Thomas Jaquin , Declan Doherty , Christopher Scott
CPC classification number: C07K16/22 , A61K39/39558 , A61K2039/505 , C07K16/2863 , C07K2317/31 , C07K2317/33 , C07K2317/73 , C07K2317/74 , A61K2300/00
Abstract: Described are cross-specific antibody molecules with binding specificity for both AREG and HBEGF. The antibody molecules may be used in methods of treatment of cancer and diseases associated with angiogenesis.
Abstract translation: 描述了对AREG和HBEGF具有结合特异性的交叉特异性抗体分子。 抗体分子可用于治疗癌症和与血管发生相关的疾病的方法。
-
公开(公告)号：US20110243955A1
公开(公告)日：2011-10-06
申请号：US13051497
申请日：2011-03-18
Applicant: Christopher Scott , Roberta Burden , Shane Olwill , Brian Walker , Jim Johnston
Inventor： Christopher Scott , Roberta Burden , Shane Olwill , Brian Walker , Jim Johnston
IPC: A61K39/395 , A61K31/7088 , C07K16/40 , C07H21/04 , A61P35/00 , A61P29/00 , A61P27/02 , A61P35/02 , A61P19/02 , A61P1/00 , A61P1/04 , A61P9/10 , C12P21/02
CPC classification number: C07K16/40 , A61K2039/505 , C07K2317/56 , C07K2317/76 , C07K2317/92
Abstract: Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members bind cathepsin S and inhibit its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis
Abstract translation: 描述的是具体的结合成员，例如 可用于治疗与组织蛋白酶S活性相关的疾病的抗体。 特异性结合成员结合组织蛋白酶S并抑制其蛋白水解活性。 结合成员可用于治疗诸如癌症，炎性疾病，神经变性疾病，自身免疫性疾病和与过度，失调或不适当的血管生成相关的疾病
-
公开(公告)号：US20090269360A1
公开(公告)日：2009-10-29
申请号：US12296704
申请日：2007-04-10
Applicant: Shane Olwill , Christopher Scott , Julie Gormley , Jaquin Thomas , Roberta Burden , Darragh McMeel , James Johnston
Inventor： Shane Olwill , Christopher Scott , Julie Gormley , Jaquin Thomas , Roberta Burden , Darragh McMeel , James Johnston
IPC: A61K39/395 , A61K33/24 , A61K31/435 , A61K31/495 , A61K31/7088 , C12N9/50 , C12N9/99 , C12N5/06 , G01N33/574
CPC classification number: C07K16/28 , A61K31/00 , A61K39/3955 , A61K39/39558 , A61K2039/505 , C07K16/40 , C07K2317/76 , G01N33/57492 , A61K2300/00
Abstract: The invention relates to a method of inhibiting chemotherapy induced upregulation of Cathepsin S on the surface of tumour cells, the method comprising the administration of a Cathepsin S inhibitor to said cells. Also provided is a therapy comprising an anti Cathepsin S antibody, in particular an anti-Cathepsin S antibody which does not inhibit the proteolytic effect of Cathepsin S but nevertheless inhibits angiogenesis and a combination treatment comprising a Cathepsin S inhibitor and a therapeutic agent.
Abstract translation: 本发明涉及一种抑制化学疗法诱导肿瘤细胞表面组织蛋白酶S上调的方法，该方法包括向所述细胞施用组织蛋白酶S抑制剂。 还提供了包含抗组织蛋白酶S抗体，特别是不抑制组织蛋白酶S的蛋白水解作用但仍然抑制血管生成并且包含组织蛋白酶S抑制剂和治疗剂的组合治疗的抗组织蛋白酶S抗体的治疗剂。
-
Patent Agency Ranking
公开(公告)号：US08747849B2
公开(公告)日：2014-06-10
申请号：US13051497
申请日：2011-03-18
Applicant: Christopher Scott , Roberta Burden , Shane Olwill , Brian Walker , Jim Johnston
Inventor： Christopher Scott , Roberta Burden , Shane Olwill , Brian Walker , Jim Johnston
IPC: A61K39/395
CPC classification number: C07K16/40 , A61K2039/505 , C07K2317/56 , C07K2317/76 , C07K2317/92
Abstract: Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members bind cathepsin S and inhibit its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis.
Abstract translation: 描述的是具体的结合成员，例如 可用于治疗与组织蛋白酶S活性相关的疾病的抗体。 特异性结合成员结合组织蛋白酶S并抑制其蛋白水解活性。 结合成员可用于治疗诸如癌症，炎性疾病，神经变性疾病，自身免疫性疾病以及与过度，失调或不合适的血管生成相关的其它疾病的疾病。
-
公开(公告)号：US20110150886A1
公开(公告)日：2011-06-23
申请号：US12988135
申请日：2009-04-17
Applicant: Jill Caswell , Shane Olwill , James Johnston , Richard Buick , Thomas Jaquin , Declan Doherty , Christopher Scott
Inventor： Jill Caswell , Shane Olwill , James Johnston , Richard Buick , Thomas Jaquin , Declan Doherty , Christopher Scott
IPC: A61K39/395 , A61K31/7088 , A61P35/00 , C07K16/18 , C07H21/04
CPC classification number: C07K16/22 , A61K39/39558 , A61K2039/505 , C07K16/2863 , C07K2317/31 , C07K2317/33 , C07K2317/73 , C07K2317/74 , A61K2300/00
Abstract: Described are cross-specific antibody molecules with binding specificity for both AREG and HBEGF. The antibody molecules may be used in methods of treatment of cancer and diseases associated with angiogenesis.
Abstract translation: 描述了对AREG和HBEGF具有结合特异性的交叉特异性抗体分子。 抗体分子可用于治疗癌症和与血管发生相关的疾病的方法。
-
公开(公告)号：US20100086551A1
公开(公告)日：2010-04-08
申请号：US12444928
申请日：2007-10-12
Applicant: Shane Olwill , Christopher Scott , James Johnston , Roberta Burden
Inventor： Shane Olwill , Christopher Scott , James Johnston , Roberta Burden
IPC: A61K39/395 , C12N5/02 , A61K31/7088 , C07K16/00 , G01N33/53
CPC classification number: A61K31/7088 , A61K39/395 , A61K45/06 , A61K48/00 , A61K2039/505 , C07K16/18 , C07K16/28 , C07K16/40 , C07K2317/73 , C07K2317/76 , C12N9/6472 , C12Q1/37 , G01N33/573 , G01N33/57496 , G01N2333/96466 , A61K2300/00
Abstract: A method of inhibiting angiogenesis in a group of cells, a tissue or an organ includes administering an antibody molecule or nucleic acid encoding an antibody molecule to the cells, tissue or organ, wherein the antibody molecule specifically binds cathepsin S, but does not inhibit proteolytic activity of cathepsin S.
Abstract translation: 一种抑制一组细胞，组织或器官中的血管发生的方法包括将抗体分子或编码抗体分子的核酸施用于细胞，组织或器官，其中抗体分子特异性结合组织蛋白酶S，但不抑制蛋白水解 组织蛋白酶S的活性
-
公开(公告)号：US20090068198A1
公开(公告)日：2009-03-12
申请号：US11918102
申请日：2006-04-10
Applicant: Christopher Scott , Roberta Burden , Shane Olwill , Brian Walker , Jim Johnston
Inventor： Christopher Scott , Roberta Burden , Shane Olwill , Brian Walker , Jim Johnston
IPC: A61K39/395 , A61K31/7052 , C07K16/00 , C07H21/00 , C12P21/00 , A61P35/00 , A61P29/00 , A61P27/02
CPC classification number: C07K16/40 , A61K2039/505 , C07K2317/56 , C07K2317/76 , C07K2317/92
Abstract: Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members binds cathepsin S and inhibits its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis.
Abstract translation: 描述的是具体的结合成员，例如 可用于治疗与组织蛋白酶S活性相关的疾病的抗体。 特异性结合成员结合组织蛋白酶S并抑制其蛋白水解活性。 结合成员可用于治疗诸如癌症，炎性疾病，神经变性疾病，自身免疫性疾病以及与过度，失调或不合适的血管生成相关的其它疾病的疾病。
-
公开(公告)号：US07939642B2
公开(公告)日：2011-05-10
申请号：US11918102
申请日：2006-04-10
Applicant: Christopher Scott , Roberta Burden , Shane Olwill , Brian Walker , Jim Johnston
Inventor： Christopher Scott , Roberta Burden , Shane Olwill , Brian Walker , Jim Johnston
IPC: C12P21/08
CPC classification number: C07K16/40 , A61K2039/505 , C07K2317/56 , C07K2317/76 , C07K2317/92
Abstract: Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members binds cathepsin S and inhibits its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis.
Abstract translation: 描述的是具体的结合成员，例如 可用于治疗与组织蛋白酶S活性相关的疾病的抗体。 特异性结合成员结合组织蛋白酶S并抑制其蛋白水解活性。 结合成员可用于治疗诸如癌症，炎性疾病，神经变性疾病，自身免疫性疾病以及与过度，失调或不合适的血管生成相关的其它疾病的疾病。
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.014 seconds)
